Search results for "lipopeptide"

showing 10 items of 50 documents

A case of Candida krusei peritonitis secondary to duodenal perforation due to Candida duodenitis.

2011

A case of a 62-year-old man with Candida krusei peritonitis secondary to duodenal perforation due to Candida duodenitis that was successfully treated with a 14-day course of caspofungin is reported. The potential role of Candida infection in the pathogenesis of peptic ulcers and duodenal perforation is considered. If this role is confirmed, antifungal treatment should be included in the therapeutic armamentarium of peptic disease.

MalePeptic Ulcermedicine.medical_specialtyAntifungal AgentsVeterinary (miscellaneous)PepticPeritonitisPeritonitisApplied Microbiology and BiotechnologyMicrobiologyGastroenterologyPathogenesisEchinocandinsLipopeptideschemistry.chemical_compoundMedical microbiologyDuodenitisCaspofunginInternal medicineCandida kruseimedicineHumansDuodenal DiseasesDuodenal PerforationPeptic diseaseCandidaDuodenal perforationDuodenitibiologyPeritonitibusiness.industrySmokingCandidiasisCandida Peritonitis Duodenal perforation Duodenitis Peptic disease Caspofungin SmokingMiddle Agedmedicine.diseasebiology.organism_classificationdigestive system diseasesTreatment OutcomechemistryIntestinal PerforationCaspofunginbusinessAgronomy and Crop Science
researchProduct

Posaconazole Activity against Candida glabrata after Exposure to Caspofungin or Amphotericin B

2008

ABSTRACT We evaluated the effects of sequential therapy with caspofungin (CAS) or amphotericin B (AMB) followed by posaconazole (POS) against Candida glabrata . The susceptibilities to POS of yeast cells pre-exposed to CAS or AMB were identical to those of untreated cells as shown by standard Clinical and Laboratory Standards Institute broth dilution, cell viability, and disk diffusion methods. We then investigated the activity of sequential regimens in an experimental model of disseminated candidiasis. CAS given at 1 mg/kg/day for 2 days followed by POS at either 15 or 30 mg/kg/day significantly reduced the counts compared to the controls, but this treatment was not superior to the use of …

MaleSettore MED/07 - Microbiologia E Microbiologia ClinicaPosaconazoleAntifungal Agentsmedicine.drug_classAntibioticsColony Count MicrobialCandida glabrataMicrobial Sensitivity TestsBiologyPharmacologyKidneyDrug Administration ScheduleMicrobiologyEchinocandinsLipopeptidesMicechemistry.chemical_compoundCaspofunginAmphotericin BAmphotericin BmedicineAnimalsHumansExperimental TherapeuticsPharmacology (medical)Viability assayPharmacologyCandida glabrataPosaconazole Candida glabrataCandidiasisTriazolesbacterial infections and mycosesbiology.organism_classificationDisseminated CandidiasisRegimenTreatment OutcomeInfectious DiseaseschemistryCaspofunginmedicine.drugAntimicrobial Agents and Chemotherapy
researchProduct

Phase II dose escalation study of caspofungin for invasive Aspergillosis.

2011

ABSTRACT Our objective was to evaluate the maximum tolerated dose of caspofungin for invasive aspergillosis (IA). The safety and pharmacokinetics of escalating dosages of caspofungin were investigated in IA. Eight patients each received caspofungin 70, 100, 150, or 200 mg once a day (QD). Dose-limiting toxicity (DLT) was defined as the same non-hematological treatment-related adverse event of grade ≥4 in 2 of 8 patients or ≥3 in 4 of 8 patients in a cohort. A total of 46 patients (median age, 61 years; 21 female; 89% with hematological malignancies) received caspofungin (9, 8, 9, and 20 patients in the 70-, 100-, 150-, and 200-mg cohorts) for a median of 24.5 days. Plasma pharmacokinetics w…

Malemedicine.medical_specialtyAntifungal AgentsDoseBiologyPharmacologyClinical TherapeuticsAspergillosisGastroenterologyDrug Administration ScheduleCohort Studieschemistry.chemical_compoundEchinocandinsLipopeptidesPharmacokineticsCaspofunginInternal medicinemedicineAspergillosisHumansPharmacology (medical)PharmacologyVoriconazoleVolume of distributionDose-Response Relationship DrugLiterMiddle Agedmedicine.diseaseSurvival AnalysisInfectious DiseasesTreatment OutcomechemistryToxicityFemaleCaspofunginmedicine.drugFollow-Up StudiesAntimicrobial agents and chemotherapy
researchProduct

A prospective, randomized study of empirical antifungal therapy for the treatment of chemotherapy-induced febrile neutropenia in children

2012

Given that the rationale for empirical antifungal therapy in neutropenic children is limited and based on adult patient data, we performed a prospective, randomized, controlled trial that evaluated 110 neutropenic children with persistent fever. Those at high risk for invasive fungal infections (IFI) received caspofungin (Arm C) or liposomal amphotericinB (Arm B); those with a lower risk were randomized to receive Arm B, C, or no antifungal treatment (Arm A). Complete response to empirical antifungal therapy was achieved in 90/104 patients (86·5%): 48/56 at high risk (85·7%) [88·0% in Arm B; 83·9% in Arm C (P = 0·72)], and 42/48 at low risk (87·5%) [87·5% in control Arm A, 80·0% Arm B, 94·1…

Malemedicine.medical_specialtyAntifungal AgentsNeutropeniaAntineoplastic AgentsOpportunistic InfectionsLower riskFever of Unknown Originlaw.inventionEchinocandinsLipopeptideschemistry.chemical_compoundRandomized controlled trialCaspofunginlawAmphotericin BInternal medicinemedicineHumansProspective StudiesChildProspective cohort studyempirical antifungal therapy children cancerbusiness.industryPatient SelectionInfantCancerHematologyLength of Staymedicine.diseaseConfidence intervalSurgeryHospitalizationTreatment OutcomeMycoseschemistryChild PreschoolFemaleCaspofunginbusinessEmpiric therapyFebrile neutropeniaBritish Journal of Haematology
researchProduct

Draft genome sequence of Pseudomonas corrugata, a phytopathogenic bacterium with potential industrial applications

2014

Pseudomonas corrugata was first described as the causal agent of a tomato disease called 'pith necrosis' yet it is considered as a biological resource in various fields such as biocontrol of plant diseases and production of industrially promising microbial biopolymers (mcl-PHA). Here we report the first draft genome sequence of this species. © 2014 Elsevier B.V.

Mcl-PHAMolecular Sequence DataBiological pest controlBacterial ProteinBioengineeringPseudomonaApplied Microbiology and BiotechnologyBacterial proteinBacterial ProteinsSolanum lycopersicumBiocontrol agentPlant pathogenPseudomonasBotanyLycopersicon esculentumWhole genome sequencingBase SequencebiologyPseudomonasfood and beveragesSequence Analysis DNAGeneral Medicinebiology.organism_classificationCyclic lipopeptideQuorum sensingPseudomonas corrugataQuorum sensingPithGenome BacterialBacteriaBiotechnologyJournal of Biotechnology
researchProduct

In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies.

2010

ABSTRACT Anidulafungin, micafungin, and caspofungin in vitro activities against Candida metapsilosis , C. orthopsilosis , and C. parapsilosis were evaluated by MICs and time-kill methods. All echinocandins showed lower MICs (mean MICs, 0.05 to 0.71 mg/liter) and the highest killing rates (−0.06 to −0.05 CFU/ml/h) for C. metapsilosis and C. orthopsilosis rather than for C. parapsilosis (mean MICs, 0.59 to 1.68 mg/liter). Micafungin and anidulafungin killing rates were greater than those determined for caspofungin. None of the echinocandins had fungicidal activity against C. parapsilosis .

Microbiological TechniquesAntifungal AgentsTime FactorsMicrobial Sensitivity TestsIn Vitro TechniquesAnidulafunginMicrobiologychemistry.chemical_compoundEchinocandinsLipopeptidesCandida metapsilosisCaspofunginmedicinepolycyclic compoundsPharmacology (medical)CandidaPharmacologybiologyMicafunginFungi imperfectibiology.organism_classificationbacterial infections and mycosesIn vitroFungicideInfectious DiseaseschemistrySusceptibilityMicafunginAnidulafunginCaspofunginEchinocandinsmedicine.drugAntimicrobial agents and chemotherapy
researchProduct

An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients.

2009

OBJECTIVES: Caspofungin was evaluated as first-line monotherapy of invasive aspergillosis (IA) in patients with haematological malignancies and undergoing autologous transplants. METHODS: Adults with proven or probable IA, defined strictly according to EORTC-MSG criteria, were eligible. Those with possible IA were enrolled, but were not evaluable for efficacy unless upgraded to proven/probable disease within 7 days of registration based on investigations performed within 48 h after enrolment. Caspofungin dosage was 70 mg (day 1) followed by 50 mg/day. The primary endpoint was the proportion of patients with complete or partial response at the end of caspofungin therapy in the modified inten…

Microbiology (medical)AdultMalemedicine.medical_specialtyAntifungal AgentsNeutropeniaAspergillosisGastroenterologyTransplantation Autologouschemistry.chemical_compoundEchinocandinsLipopeptidesYoung AdultCaspofunginInternal medicineClinical endpointmedicineAspergillosisHumansPharmacology (medical)Survival rateSurvival analysisAgedPharmacologyAged 80 and overSurrogate endpointbusiness.industryMiddle Agedmedicine.diseaseSurvival AnalysisSurgeryTransplantationAcute Leukaemia; Fungal Infections; Echinocandins; Bone-Marrow-Transplantation; Stem-Cell Transplants; Mycoses Study-Group; Fungal-Infections; Prognostic-Factors; European-Organization; Amphotericin-B; Consensus; Epidemiology; VoriconazoleInfectious DiseasesTreatment OutcomechemistryHematologic NeoplasmsFemaleCaspofunginbusinessThe Journal of antimicrobial chemotherapy
researchProduct

Comparison between Disk Diffusion and Microdilution Methods for Determining Susceptibility of Clinical Fungal Isolates to Caspofungin

2007

ABSTRACT We compared the caspofungin (CAS) susceptibility testing results generated by the disk diffusion (DD) assay with the results of the Clinical and Laboratory Standards Institute (CLSI) broth microdilution (BD) reference method for 106 yeast isolates. The isolates represented 11 different fungal species, including Candida albicans ( n = 50), C. parapsilosis ( n = 10), C. glabrata ( n = 10), C. tropicalis ( n = 10), C. guillermondii ( n = 6), C. rugosa ( n = 5), C. krusei ( n = 5), C. kefyr ( n = 2), C. pelliculosa ( n = 2), Saccharomyces cerevisiae ( n = 3), and Geotrichum candidum ( n = 3). The DD assay was performed in supplemented Mueller-Hinton agar with CAS, which was tested at c…

Microbiology (medical)Settore MED/07 - Microbiologia E Microbiologia ClinicaSusceptibility testingAntifungal AgentsInhibition zonefood.ingredientGeotrichumMicrobial Sensitivity TestsMycologyMicrobiologyDiffusionEchinocandinsLipopeptideschemistry.chemical_compoundfoodCaspofunginCandida albicansAgarCandida albicansCaspofungin Candida Disk diffusion antimicrobial testingbiologyBroth microdilutionFungibiology.organism_classificationYeastchemistryCaspofunginJournal of Clinical Microbiology
researchProduct

Poriferan survivin exhibits a conserved regulatory role in the interconnected pathways of cell cycle and apoptosis

2010

Survivin orchestrates intracellular pathways during cell division and apoptosis. Its central function as mitotic regulator and inhibitor of cell death has major implications for tumor cell proliferation. Analyses in early-branching Metazoa so far propose an exclusive role of survivin as a chromosomal passenger protein, whereas only later during evolution a complementary antiapoptotic function might have arisen, concurrent with increased organismal complexity. To lift the veil on the ancestral function(s) of this key regulator, a survivin-like protein (SURVL) of one of the earliest-branching metazoan taxa was identified and functionally characterized. SURVL of the sponge Suberites domuncula …

Programmed cell deathCell divisionRecombinant Fusion ProteinsMolecular Sequence DataApoptosisTransfectionCell LineInhibitor of Apoptosis ProteinsLipopeptidesSurvivinAnimalsHumansAmino Acid SequenceMolecular BiologyMitosisGeneticsOriginal PaperBase SequencebiologyCell CycleCell BiologyCell cyclebiology.organism_classificationCell biologySuberites domunculaCell cultureCaspasesSuberitesSequence AlignmentCell DivisionIntracellularCadmiumCell Death & Differentiation
researchProduct

Coiled-Coil Lipopeptides Mimicking the Prehairpin Intermediate of Glycoprotein gp41

2009

Protein ConformationMolecular Sequence DataRetroviridae ProteinsPeptideGp41CatalysisLipopeptides03 medical and health sciences0302 clinical medicineAnimalsAmino Acid Sequence030304 developmental biologychemistry.chemical_classificationCoiled coil0303 health sciencesMembrane GlycoproteinsPhosphatidylethanolaminesMolecular MimicryGeneral ChemistryGeneral MedicineVirus InternalizationAnti-Retroviral AgentschemistryBiochemistryPhosphatidylcholinesGlycoprotein030217 neurology & neurosurgeryAngewandte Chemie
researchProduct